phosphocreatine and Huntington-Disease

phosphocreatine has been researched along with Huntington-Disease* in 11 studies

Trials

2 trial(s) available for phosphocreatine and Huntington-Disease

ArticleYear
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
    Neurology, 2005, May-10, Volume: 64, Issue:9

    Topics: Administration, Oral; Aspartic Acid; Body Weight; Brain; Creatine; Creatinine; Dose-Response Relationship, Drug; Energy Metabolism; Humans; Huntington Disease; Magnetic Resonance Spectroscopy; Neuropsychological Tests; Patient Compliance; Phosphocreatine; Pilot Projects; Treatment Outcome; Up-Regulation

2005
Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study.
    Neurology, 2003, Jul-08, Volume: 61, Issue:1

    Topics: Adenosine Triphosphate; Aspartic Acid; Brain; Choline; Creatine; Diarrhea; Dietary Supplements; Dose-Response Relationship, Drug; Humans; Huntington Disease; Magnetic Resonance Spectroscopy; Muscle, Skeletal; Nausea; Neuropsychological Tests; Phosphocreatine; Pilot Projects; Reference Values; Safety; Treatment Outcome

2003

Other Studies

9 other study(ies) available for phosphocreatine and Huntington-Disease

ArticleYear
Thalamic metabolic abnormalities in patients with Huntington's disease measured by magnetic resonance spectroscopy.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2013, Volume: 46, Issue:8

    Huntington's disease (HD) is a neurologic disorder that is not completely understood; its fundamental physiological mechanisms and chemical effects remain somewhat unclear. Among these uncertainties, we can highlight information about the concentrations of brain metabolites, which have been widely discussed. Concentration differences in affected, compared to healthy, individuals could lead to the development of useful tools for evaluating the progression of disease, or to the advance of investigations of different/alternative treatments. The aim of this study was to compare the thalamic concentration of metabolites in HD patients and healthy individuals using magnetic resonance spectroscopy. We used a 2.0-Tesla magnetic field, repetition time of 1500 ms, and echo time of 135 ms. Spectra from 40 adult HD patients and 26 control subjects were compared. Quantitative analysis was performed using the LCModel method. There were statistically significant differences between HD patients and controls in the concentrations of N-acetylaspartate+N-acetylaspartylglutamate (NAA+NAAG; t-test, P<0.001), and glycerophosphocholine+phosphocholine (GPC+PCh; t-test, P=0.001) relative to creatine+phosphocreatine (Cr+PCr). The NAA+NAAG/Cr+PCr ratio was decreased by 9% and GPC+PCh/Cr+PCr increased by 17% in patients compared with controls. There were no correlations between the concentration ratios and clinical features. Although these results could be caused by T1 and T2 changes, rather than variations in metabolite concentrations given the short repetition time and long echo time values used, our findings point to thalamic dysfunction, corroborating prior evidence.

    Topics: Adolescent; Adult; Aged; Aspartic Acid; Case-Control Studies; Creatine; Deuterium; Dipeptides; Female; Glycerylphosphorylcholine; Humans; Huntington Disease; Magnetic Resonance Spectroscopy; Male; Middle Aged; Motor Activity; Phosphocreatine; Phosphorylcholine; Thalamic Diseases; Thalamus; Trinucleotide Repeats; Young Adult

2013
Early alterations of brain cellular energy homeostasis in Huntington disease models.
    The Journal of biological chemistry, 2012, Jan-06, Volume: 287, Issue:2

    Brain energy deficit has been a suggested cause of Huntington disease (HD), but ATP depletion has not reliably been shown in preclinical models, possibly because of the immediate post-mortem changes in cellular energy metabolism. To examine a potential role of a low energy state in HD, we measured, for the first time in a neurodegenerative model, brain levels of high energy phosphates using microwave fixation, which instantaneously inactivates brain enzymatic activities and preserves in vivo levels of analytes. We studied HD transgenic R6/2 mice at ages 4, 8, and 12 weeks. We found significantly increased creatine and phosphocreatine, present as early as 4 weeks for phosphocreatine, preceding motor system deficits and decreased ATP levels in striatum, hippocampus, and frontal cortex of R6/2 mice. ATP and phosphocreatine concentrations were inversely correlated with the number of CAG repeats. Conversely, in mice injected with 3-nitroproprionic acid, an acute model of brain energy deficit, both ATP and phosphocreatine were significantly reduced. Increased creatine and phosphocreatine in R6/2 mice was associated with decreased guanidinoacetate N-methyltransferase and creatine kinase, both at the protein and RNA levels, and increased phosphorylated AMP-dependent protein kinase (pAMPK) over AMPK ratio. In addition, in 4-month-old knock-in Hdh(Q111/+) mice, the earliest metabolic alterations consisted of increased phosphocreatine in the frontal cortex and increased the pAMPK/AMPK ratio. Altogether, this study provides the first direct evidence of chronic alteration in homeostasis of high energy phosphates in HD models in the earliest stages of the disease, indicating possible reduced utilization of the brain phosphocreatine pool.

    Topics: Adenosine Triphosphate; Animals; Brain Chemistry; Convulsants; Disease Models, Animal; Energy Metabolism; Frontal Lobe; Gene Knock-In Techniques; Guanidinoacetate N-Methyltransferase; Huntington Disease; Mice; Mice, Transgenic; Nerve Tissue Proteins; Nitro Compounds; Phosphocreatine; Propionates

2012
Abnormal response to cortical activation in early stages of Huntington disease.
    Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:7

    We wished to identify noninvasive in vivo biomarkers of brain energy deficit in Huntington disease.. We studied 15 early affected patients (mean motor United Huntington Disease Rating Scale, 18 ± 9) and 15 age- and sex-matched controls. We coupled (31)phosphorus nuclear magnetic resonance spectroscopy with activation of the occipital cortex in order to measure the relative concentrations of adenosine triphosphate, phosphocreatine, and inorganic phosphate before, during, and after visual stimulation.. In controls, we observed an 11% increase in the inorganic phosphate/phosphocreatine ratio (P = .024) and a 13% increase in the inorganic phosphate/adenosine triphosphate ratio (P = .016) during brain activation, reflecting increased adenosine diphosphate concentrations. Subsequently, controls had a return to baseline levels during recovery (P = .012 and .022, respectively). In contrast, both ratios were unchanged in patients during and after visual stimulation.. (31)Phosphorus nuclear magnetic resonance spectroscopy could provide functional biomarkers of brain energy deficit to monitor therapeutic efficacy in Huntington disease.

    Topics: Adenosine Triphosphate; Case-Control Studies; Cerebral Cortex; Female; Humans; Huntington Disease; Linear Models; Magnetic Resonance Spectroscopy; Male; Phosphates; Phosphocreatine; Phosphorus Isotopes; Radionuclide Imaging

2012
Impaired brain creatine kinase activity in Huntington's disease.
    Neuro-degenerative diseases, 2011, Volume: 8, Issue:4

    Huntington's disease (HD) is associated with impaired energy metabolism in the brain. Creatine kinase (CK) catalyzes ATP-dependent phosphorylation of creatine (Cr) into phosphocreatine (PCr), thereby serving as readily available high-capacity spatial and temporal ATP buffering.. Substantial evidence supports a specific role of the Cr/PCr system in neurodegenerative diseases. In the brain, the Cr/PCr ATP-buffering system is established by a concerted operation of the brain-specific cytosolic enzyme BB-CK and ubiquitous mitochondrial uMt-CK. It is not yet established whether the activity of these CK isoenzymes is impaired in HD.. We measured PCr, Cr, ATP and ADP in brain extracts of 3 mouse models of HD - R6/2 mice, N171-82Q and HdhQ(111) mice - and the activity of CK in cytosolic and mitochondrial brain fractions from the same mice.. The PCr was significantly increased in mouse HD brain extracts as compared to nontransgenic littermates. We also found an approximately 27% decrease in CK activity in both cytosolic and mitochondrial fractions of R6/2 and N171-82Q mice, and an approximately 25% decrease in the mitochondria from HdhQ(111) mice. Moreover, uMt-CK and BB-CK activities were approximately 63% lower in HD human brain samples as compared to nondiseased controls.. Our findings lend strong support to the role of impaired energy metabolism in HD, and point out the potential importance of impairment of the CK-catalyzed ATP-buffering system in the etiology of HD.

    Topics: Animals; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Creatine Kinase, BB Form; Disease Models, Animal; Huntington Disease; Mice; Mice, Transgenic; Mitochondria; Phosphocreatine

2011
Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease.
    Neurochemistry international, 2006, Volume: 48, Issue:2

    The neuropathological and clinical symptoms of Huntington's disease (HD) can be simulated in animal model with systemic administration of 3-nitropropionic acid (3-NP). Energy defects in HD could be ameliorated by administration of coenzyme Q(10) (CoQ(10)), creatine, or nicotinamid. We studied the activity of creatine kinase (CK) and the function of mitochondrial respiratory chain in the brain of aged rats administered with 3-NP with and without previous application of antioxidants CoQ(10)+vitamin E. We used dynamic and steady-state methods of in vivo phosphorus magnetic resonance spectroscopy ((31)P MRS) for determination of the pseudo-first order rate constant (k(for)) of the forward CK reaction, the phosphocreatine (PCr) to adenosinetriphosphate (ATP) ratio, intracellular pH(i) and Mg(i)(2+) content in the brain. The respiratory chain function of isolated mitochondria was assessed polarographically; the concentration of CoQ(10) and alpha-tocopherol by HPLC. We found significant elevation of k(for) in brains of 3-NP rats, reflecting increased rate of CK reaction in cytosol. The function of respiratory chain in the presence of succinate was severely diminished. The activity of cytochromeoxidase and mitochondrial concentration of CoQ(10) was unaltered; tissue content of CoQ(10) was decreased in 3-NP rats. Antioxidants CoQ(10)+vitamin E prevented increase of k(for) and the decrease of CoQ(10) content in brain tissue, but were ineffective to prevent the decline of respiratory chain function. We suppose that increased activity of CK system could be compensatory to decreased mitochondrial ATP production, and CoQ(10)+vitamin E could prevent the increase of k(for) after 3-NP treatment likely by activity of CoQ(10) outside the mitochondria. Results of our experiments contributed to elucidation of mechanism of beneficial effect of CoQ(10) administration in HD and showed that the rate constant of CK is a sensitive indicator of brain energy disorder reflecting therapeutic effect of drugs that could be used as a new in vivo biomarker of neurodegenerative diseases.

    Topics: Adenosine Triphosphate; Animals; Brain; Coenzymes; Creatine Kinase; Disease Models, Animal; Electron Transport Complex IV; Energy Metabolism; Huntington Disease; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Male; Oxidative Phosphorylation; Phosphocreatine; Rats; Rats, Wistar; Ubiquinone; Vitamin E

2006
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:6

    Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the IT-15 gene; however, it remains unknown how the mutation leads to selective neurodegeneration. Several lines of evidence suggest impaired mitochondrial function as a component of the neurodegenerative process in HD. We assessed energy metabolism in the skeletal muscle of 15 HD patients and 12 asymptomatic mutation carriers in vivo using 31P magnetic resonance spectroscopy. Phosphocreatine recovery after exercise is a direct measure of ATP synthesis and was slowed significantly in HD patients and mutation carriers in comparison to age- and gender-matched healthy controls. We found that oxidative function is impaired to a similar extent in manifest HD patients and asymptomatic mutation carriers. Our findings suggest that mitochondrial dysfunction is an early and persistent component of the pathophysiology of HD.

    Topics: Adenosine Triphosphate; Adult; Case-Control Studies; Energy Metabolism; Exercise; Female; Humans; Huntingtin Protein; Huntington Disease; Immunohistochemistry; Magnetic Resonance Spectroscopy; Male; Middle Aged; Mitochondrial Diseases; Muscle, Skeletal; Mutation; Nerve Tissue Proteins; Nuclear Proteins; Phosphocreatine; Reaction Time

2005
Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy.
    Journal of neuroscience research, 2001, Dec-01, Volume: 66, Issue:5

    Intrastriatal injection of quinolinic acid (QA) provides an animal model of Huntington disease. In vivo (1)H NMR spectroscopy was used to measure the neurochemical profile non-invasively in seven animals 5 days after unilateral injection of 150 nmol of QA. Concentration changes of 16 metabolites were measured from 22 microl volume at 9.4 T. The increase of glutamine ((+25 +/- 14)%, mean +/- SD, n = 7) and decrease of glutamate (-12 +/- 5)%, N-acetylaspartate (-17 +/- 6)%, taurine (-14 +/- 6)% and total creatine (-9 +/- 3%) were discernible in each individual animal (P < 0.005, paired t-test). Metabolite concentrations in control striata were in excellent agreement with biochemical literature. The change in glutamate plus glutamine was not significant, implying a shift in the glutamate-glutamine interconversion, consistent with a metabolic defect at the level of neuronal-glial metabolic trafficking. The most significant indicator of the lesion, however, were the changes in glutathione ((-19 +/- 9)%, P < 0.002)), consistent with oxidative stress. From a comparison with biochemical literature we conclude that high-resolution in vivo (1)H NMR spectroscopy accurately reflects the neurochemical changes induced by a relatively modest dose of QA, which permits one to longitudinally follow mitochondrial function, oxidative stress and glial-neuronal metabolic trafficking as well as the effects of treatment in this model of Huntington disease.

    Topics: Amino Acids; Animals; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Energy Metabolism; Female; Glucose; Huntington Disease; Magnetic Resonance Spectroscopy; Mitochondria; Neostriatum; Neuroglia; Neurons; Neurotoxins; Oxidative Stress; Phosphocreatine; Quinolinic Acid; Rats; Rats, Inbred F344

2001
Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy.
    Annals of neurology, 2000, Volume: 48, Issue:1

    We studied in vivo muscle energy metabolism in patients with Huntington's disease (HD) and dentatorubropallidoluysian atrophy (DRPLA) using 31P magnetic resonance spectroscopy (MRS). Twelve gene-positive HP patients (4 presymptomatic patients) and 2 gene-positive DRPLA patients (1 presymptomatic patient) were studied. 31P-MRS at rest showed a reduced phosphocreatine-to-inorganic phosphate ratio in the symptomatic HD patients and DRPLA patient. Muscle adenosine triphosphate/(phosphocreatine + inorganic phosphate) at rest was significantly reduced in both groups of symptomatic and presymptomatic HD subjects and was below the normal range in the 2 DRPLA subjects. During recovery from exercise, the maximum rate of mitochondrial adenosine triphosphate production was reduced by 44% in symptomatic HD patients and by 35% in presymptomatic HD carriers. The maximum rate of mitochondrial adenosine triphosphate production in muscle was also reduced by around 46% in the 2 DRPLA subjects. Our findings show that HD and DRPLA share a deficit of in vivo mitochondrial oxidative metabolism, supporting a role for mitochondrial dysfunction as a factor involved in the pathogenesis of these polyglutamine repeat-mediated neurodegenerative disorders. The identification of 31P-MRS abnormalities may offer a surrogate biochemical marker by which to study disease progression and the effects of treatment in HD and DRPLA.

    Topics: Adenosine Triphosphate; Adult; Brain; Energy Metabolism; Female; Humans; Huntington Disease; Magnetic Resonance Spectroscopy; Male; Middle Aged; Mitochondria; Muscle, Skeletal; Myoclonic Epilepsies, Progressive; Phosphates; Phosphocreatine

2000
Genetic counselling and the physician.
    Canadian Medical Association journal, 1968, Nov-16, Volume: 99, Issue:19

    Topics: Abortion, Legal; Adult; Albinism; Chromosome Aberrations; Chromosome Disorders; Congenital Abnormalities; Counseling; Family Planning Services; Female; Genes, Dominant; Genes, Recessive; Genetic Diseases, Inborn; Hand Deformities, Acquired; Hemophilia A; Humans; Huntington Disease; Karyotyping; Male; Muscular Dystrophies; Pedigree; Phosphocreatine; Pregnancy; Retinoblastoma; Sex Chromosome Aberrations; Sterilization, Reproductive

1968